Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
  Avian & pandemic flu
  Cancer
  Earthquakes
  Floods
  HIV & AIDS
  Malaria
  Stem cells
  Volcanoes
  Water
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Indonesia
  Ireland
  Israel
  Italy
  Jamaica
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malaysia
  Malta
  Mexico
  Montenegro
  Morocco
  Mozambique
  Namibia
  Netherlands
  New Zealand
  Nigeria
  Norway
  Panama
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Sri Lanka
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Thailand
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States
  Vietnam


This page was published on 07/03/2006
Published: 07/03/2006

   Special Collections

Last Update: 07-03-2006  
Related category(ies):
Health & life sciences  |  Special Collections

 

Add to PDF "basket"

EU projects Virgil and Vizier put the ‘V' in viral research

The ‘V' symbol has travelled the decades under different guises. It stood for ‘victory' in times of war, as a sign of peace during the sixties and has taken on a new significance in the scientific battle against viral contagions. Two EU-funded projects, Virgil and Vizier, are on the front lines.

Eye-catching logo of one of Virgil's platforms for clinical surveillance of viral drug resistance in Europe. © Virgil Network of Excellence
Eye-catching logo of one of Virgil's platforms for clinical surveillance of viral drug resistance in Europe.
© Virgil Network of Excellence
Infectious diseases are formidable foes in a battle being waged to eradicate or, at least, contain them. For example, strains of harmful bacteria are now so resistant to many antibiotics that diseases, such as tuberculosis and pneumonia, are making a comeback. Likewise, viruses mutate and develop resistance to anti-viral drugs – something already seen with HIV. Could we end up with a ‘super strain' of influenza that defies modern science?

The EU-supported Virgil research network is making sure that Europe's doctors and scientists working on viral resistance pool their effort to prevent the doom scenario of a pandemic strain of influenza. Professionals from some 20 institutes in France, Germany, Italy, Spain, Austria, The Netherlands and the UK are helping to organise and run seven virtual platforms for research on resistance to drugs in hepatitis B and C as well as in influenza. To date, the network counts some 60 organisations in 14 countries.

Virgil, or the ‘European Surveillance Network for Vigilance against Viral Resistance', kicked off in May 2004 and will spend the next four years (and in principle beyond) and €9 million in EU funds structuring and coordinating what was previously a fragmented research field. Several of the platforms have reported results which are already helping Europe keep guard against these virulent enemies.

©For example, the Virgil-Surveil platform designed a standardised swab form to be used Europe-wide for providing information on current use of antivirals and to collect clinical signs and symptoms of resistant strains. Virgil-Clinvir has set up several central repositories for studying hepatitis and flu resistance. Meanwhile, Virgil-Innotech has discovered or refined new cell lines for hepatitis C and influenza, and a DNA on a chip programme is underway to analyse drug-resistant viruses.

New drugs, too
As Virgil keeps a vigil on viral resistance, Vizier – ‘Comparative Structural Genomics on Viral Enzymes Involved in Replication' – will be working to develop new drugs to keep one step ahead of them. Looking at influenza (of particular interest in light of growing avian flu concerns), four drugs are currently available for treating flu infection. These are the first-generation anti-influenza drugs Amantadine and Rimantadine, and the second-generation anti-influenza drugs Oseltamivir (Tamiflu) and Zanamivir (Relenza).

Today, resistance to Amantadine and Rimantadine is common. Indeed, H5N1 ‘avian flu' strain, known to be resistant to these drugs, are already circulating in Asia. Oseltamivir and Zanamivir are more potent, say the researchers behind the EU-funded Vizier project, and resistance does not appear so readily. But it could be only a matter of time. Recently, Oseltamivir-resistant H5N1 strains have been identified in infected patients in Asia.

“Since the resistance profiles of Oseltamivir and Zanamivir overlap to some extent,” note the Vizier scientists in a statement, “it is of utmost importance to have other drugs at hand that have a different mode of action – and thus a different resistance profile.”

Groups from nearly 30 institutions around the globe, including Russian and African teams, are studying various targets of the replication cycle, including the non-structural proteins of influenza and other RNA viruses. The five-year Vizier project is putting €13 million in EU funding towards understanding the precise function and unravelling the structure of these proteins.

“[This] will be key to identifying compounds that inhibit their function and thus the replication of influenza viruses,” predicts the team. Their findings should open new paths for drugs developed to treat a diverse set of RNA viruses, including measles, dengue fever, hepatitis C, and the now widely publicised avian influenza and SARS. This could save millions of lives and many more millions in health care costs worldwide. Measles, for example, infects 45 million people annually, resulting in around 1 million deaths. Hepatitis C cases exceed 180 million annually, while dengue fever strikes 300 million and influenza up to hundreds of millions every year.

Project information, EU press briefings

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Virgil

Vizier

Call for avian flu projects (Europa)

EU-funded research on pandemic and avian influenza (press briefing, 7 February 2006, Europa)


Contacts
Research DG contacts
  Top   Research Information Center